Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
复制标题
DOI：
10.1016/j.tips.2015.11.004
复制
发表时间：
2016-03
影响因子：
13.8
通讯作者：
Kranz DM
中科院分区：
文献类型：
--
作者：
Harris DT;Kranz DM
T细胞的肿瘤杀伤特性为治疗癌症提供了巨大的机会。连续性T细胞疗法已经开始通过赋予功能多样的T细胞库以遗传修饰的肿瘤特异性识别受体来利用这种潜力。通常，这种抗原识别功能由αβ T细胞受体（TCR）介导，但目前开发的主要治疗形式是称为嵌合抗原受体（汽车）的合成构建体。虽然基于CAR的过继细胞疗法已经显示出巨大的前景，但与αβ TCR相比，它们的基本机制特性研究得不太详细。在这篇综述中，我们比较和对比了TCR与汽车的各种特征，目的是突出需要解决的问题，以充分利用两者的治疗潜力。
The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors. Normally, this antigen recognition function is mediated by an αβ T cell receptor (TCR), but the dominant therapeutic forms currently in development are synthetic constructs called chimeric antigen receptors (CARs). While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of αβ TCRs. In this review, we compare and contrast various features of TCRs versus CARs, with a goal of highlighting issues that need to be addressed to fully exploit the therapeutic potential of both.